ONTXW
Income statement / Annual
Last year (2020), Onconova Therapeutics Inc. Warrants's total revenue was $231.00 K,
a decrease of 89.42% from the previous year.
In 2020, Onconova Therapeutics Inc. Warrants's net income was -$25.16 M.
See Onconova Therapeutics Inc. Warrants,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
| Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
| Operating Revenue |
$231.00 K |
$2.18 M |
$1.23 M |
$787.00 K |
$5.55 M |
$11.46 M |
$800.00 K |
$4.75 M |
$46.19 M |
$1.49 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$231.00 K
|
$2.18 M
|
$1.23 M
|
$787.00 K
|
$5.55 M
|
$11.46 M
|
$800.00 K
|
$4.75 M
|
$46.19 M
|
$1.49 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$16.90 M
|
$15.54 M
|
$16.92 M
|
$19.12 M
|
$20.07 M
|
$25.90 M
|
$49.43 M
|
$50.18 M
|
$52.76 M
|
$22.62 M
|
| General & Administrative Expenses |
$8.33 M
|
$8.35 M
|
$7.59 M
|
$7.41 M
|
$0.00
|
$9.53 M
|
$15.12 M
|
$16.79 M
|
$0.00
|
$6.44 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.33 M
|
$8.35 M
|
$7.59 M
|
$7.41 M
|
$0.00
|
$9.53 M
|
$15.12 M
|
$16.79 M
|
$0.00
|
$6.44 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$9.18 M
|
$0.00
|
$0.00
|
$0.00
|
$15.71 M
|
$0.00
|
| Operating Expenses |
$25.22 M
|
$23.88 M
|
$24.51 M
|
$26.52 M
|
$29.25 M
|
$35.43 M
|
$64.54 M
|
$66.98 M
|
$68.47 M
|
$29.06 M
|
| Cost And Expenses |
$25.22 M
|
$23.88 M
|
$24.51 M
|
$26.52 M
|
$29.25 M
|
$35.43 M
|
$64.54 M
|
$66.98 M
|
$68.47 M
|
$29.06 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.00 K
|
$4.00 K
|
$8.61 M
|
$19.00 K
|
| Depreciation & Amortization |
$13.00 K
|
$14.00 K
|
$55.00 K
|
$88.00 K
|
$96.00 K
|
$150.00 K
|
$434.00 K
|
$446.00 K
|
$319.00 K
|
$316.00 K
|
| EBITDA |
-$24.98 M |
-$21.69 M |
-$20.64 M |
-$23.99 M |
-$19.56 M |
-$23.81 M |
-$63.23 M |
-$61.66 M |
-$20.99 M |
-$25.96 M |
| EBITDA Ratio |
-108.14
|
-9.93
|
-16.81
|
-30.48
|
-3.53
|
-2.08
|
-79.03
|
-12.97
|
-0.45
|
-17.46
|
| Operating Income Ratio |
-108.19
|
-9.94
|
-18.96
|
-32.7
|
-4.27
|
-2.09
|
-79.68
|
-13.09
|
-0.48
|
-18.54
|
| Total Other Income/Expenses Net |
-$160.00 K
|
$206.00 K
|
$2.75 M
|
$1.66 M
|
$4.05 M
|
-$35.00 K
|
-$32.00 K
|
$101.00 K
|
-$7.63 M
|
$1.28 M
|
| Income Before Tax |
-$25.15 M
|
-$21.49 M
|
-$20.53 M
|
-$24.08 M
|
-$19.65 M
|
-$24.01 M
|
-$63.78 M
|
-$62.12 M
|
-$29.91 M
|
-$26.29 M
|
| Income Before Tax Ratio |
-108.89
|
-9.85
|
-16.72
|
-30.6
|
-3.54
|
-2.1
|
-79.72
|
-13.07
|
-0.65
|
-17.68
|
| Income Tax Expense |
$4.00 K
|
$10.00 K
|
$124.00 K
|
$13.00 K
|
$14.00 K
|
$16.00 K
|
$19.00 K
|
$435.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$25.16 M
|
-$21.50 M
|
-$20.57 M
|
-$24.09 M
|
-$19.67 M
|
-$23.98 M
|
-$63.68 M
|
-$62.54 M
|
-$29.91 M
|
-$26.29 M
|
| Net Income Ratio |
-108.9
|
-9.85
|
-16.75
|
-30.61
|
-3.55
|
-2.09
|
-79.6
|
-13.16
|
-0.65
|
-17.68
|
| EPS |
-0.14 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS Diluted |
-0.14 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Weighted Average Shares Out |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares Out Diluted |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
